This modification is revealed by changes in the dispersive parameters and variations in the relative temperature gradients.
Agonist pMHC binding to TCR in T cells is revealed by changes in mobility.
Finally, TFBS variability can be revealed by targeted changes in cell homeostasis, such as by treatment with drugs that modulate specific signalling pathways 111– 111.
Any potential purging of deleterious mutations should be revealed by tracking fitness changes within large, self-fertilizing populations over a number of generations.
Moreover, by varying the lumenal and cytosolic components in parallel samples, the requirement for individual factors during retrotranslocation may be revealed by even subtle changes in the kinetics of substrate retrotranslocation.
Although the alteration of a TF cannot be detected directly from the expression changes of its corresponding mRNA, we expect that alteration of the TF can be revealed by using the expression changes of its target genes.
The physical interactions can be revealed by monitoring the real-time fluorescence changes (8.6% fluorescence increase in mammals and 27.6% in plants); their correlations to functional exertion were shown with a GTPase accelerating activity assay and further confirmed by measurement of Kd.
Thus, the functional changes might not be revealed by gene-phenotype correlation tests, and most gene-/gene set-based approaches based on this rationale cannot be applied on such data sets.
Our aim is to identify and study the type and severity of changes that can be revealed by neurological, cognitive, psychiatric, neuroimaging, and neurophysiological techniques as well as metabolic and genetic analyses in a cohort of subject with predefined neonatal adverse events by means of a careful and lifelong follow-up.
These differences are revealed by geometrical changes at a macroscopic scale upon deformation, but are likely the result of changes in the microscopic structure of the cornea.
